Cordlife Group Limited (CLIFF) Stock Analysis & Winston Score
Cordlife Group Limited is a Singapore-based company that stores umbilical cord blood and cord tissue for families after a baby is born. The idea is that these samples contain stem cells, which could potentially be used to treat certain diseases later in life. Cordlife serves parents across Southeast Asia and parts of South Asia, including markets like Singapore, India, Indonesia, the Philippines, and Hong Kong. The company charges families an upfront fee plus annual storage fees to keep their samples safe in special facilities, making it a mix of one-time and recurring revenue. Cordlife has built its business around trust and accreditation, since parents are handing over something irreplaceable. However, the company has faced serious regulatory and reputational damage after a 2023 incident in Singapore where stored samples were exposed to improper temperatures, raising questions about storage quality. Rebuilding customer confidence and regulatory standing is the central challenge the business faces going forward.
Winston Score: 27/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (8/30)
- Growth: Mixed (7/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Mixed (6/15)
Key Facts
Price: $0.15
Market Cap: $39M
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Exchange: Other OTC
